Overview

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effectiveness of two antipsychotic medications, Risperdal® Consta® versus Abilify®, over a 2-year treatment period in the long-term maintenance of patients with schizophrenia.
Phase:
Phase 4
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Collaborator:
Janssen, LP
Treatments:
Aripiprazole
Risperidone